{"url_path":"/sec/tpst/8-k/2026-06-23/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-23","source_url":"https://www.sec.gov/Archives/edgar/data/1544227/0001193125-26-278068-index.html","accession_number":"0001193125-26-278068","cik":"0001544227","ticker":"TPST","issuer_name":"Tempest Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1544227/0001193125-26-278068-index.html","primary_entity_key":"0001544227","primary_entity_name":"Tempest Therapeutics, Inc."},"word_count":332,"has_tables":true,"body_markdown":"Item 5.07\n\nSubmission of Matters to a Vote of Security Holders.\n\nOn June 18, 2026, the Company held its 2026 Special Meeting of Stockholder (the “Special Meeting”). The final results for each of the proposals submitted to a vote of the Company’s stockholders at the Special Meeting are set forth below. These proposals are described in detail in the Proxy Statement.\n\nProposal 1. Approval of an issuance of the Company’s common stock pursuant to Nasdaq Rule 5635.\n\nThe Company’s stockholders approved, pursuant to Nasdaq Rule 5635, the issuance of up to (i) 925,927 shares of the Company’s common stock, par value $0.001 per share (“common stock”) issuable upon the exercise of outstanding Series A Warrants, (ii) 925,927 shares of the Company’s common stock issuable upon the exercise of outstanding Series B Warrants which were issued in connection with our private placement offering pursuant to the terms of the securities purchase agreement dated March 20, 2026 by and among the Company and the investors thereto. The final voting results were as follows:\n\n \n\nVotes For\n \nVotes Against\n \nAbstentions\n\n9,090,763\n \n398,678\n \n18,310\n\nProposal 2. Approval of an issuance of the Company’s common stock pursuant to Nasdaq Rule 5635.\n\nThe Company’s stockholders approved, pursuant to Nasdaq Rule 5635, the issuance of up to 2,344,828 shares of the Company’s common stock issuable upon the exercise of outstanding Common Warrants which were issued in connection with an Inducement Offer to Exercise Common Stock Purchase Warrants Issued in November 2025 pursuant to the terms of the letter agreement dated May 28, 2026 by and between the Company and the investor thereto. The final voting results were as follows:\n\n \n\nVotes For\n \nVotes Against\n \nAbstentions\n\n9,091,165\n \n398,276\n \n18,310\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \nTEMPEST THERAPEUTICS, INC.\n\nDate: June 22, 2026\n \n\n \nBy:\n \n\n/s/ Matthew Angel\n\n \n\n \nName:\n \nMatthew Angel\n\n \n\n \nTitle:\n \nPresident and Chief Executive Officer"}